Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Liebes

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignanciesM A Rosenthal, D Dennis, L Liebes, et al.
Oncogene|January 15, 2008
Epidermal growth factor receptor activation in prostate cancer by three novel missense mutationsC Q Cai, Y Peng, M T Buckley, et al.
Annals of Internal Medicine|July 15, 1990
Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group StudyH Hochster, D Dieterich, S Bozzette, et al.
Annals of Internal Medicine|March 13, 1999
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258R M Gulick, V McAuliffe, J Holden-Wiltse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 1998
Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancerE L Kramer, L Liebes, C Wasserheit, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1993
Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I studyE L Kramer, S J DeNardo, L Liebes, et al.
Gynecologic Oncology|October 31, 2006
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancerD S Alberts, M Markman, F Muggia, et al.
Journal of Liposome Research|February 27, 2003
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studiesJ Szebeni, L Baranyi, S Savay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton, J P Eder, A C Pavlick, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignanciesM A Rosenthal, D Dennis, L Liebes, et al.
Oncogene|January 15, 2008
Epidermal growth factor receptor activation in prostate cancer by three novel missense mutationsC Q Cai, Y Peng, M T Buckley, et al.
Annals of Internal Medicine|July 15, 1990
Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group StudyH Hochster, D Dieterich, S Bozzette, et al.
Annals of Internal Medicine|March 13, 1999
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258R M Gulick, V McAuliffe, J Holden-Wiltse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 1998
Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancerE L Kramer, L Liebes, C Wasserheit, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1993
Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I studyE L Kramer, S J DeNardo, L Liebes, et al.
Gynecologic Oncology|October 31, 2006
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancerD S Alberts, M Markman, F Muggia, et al.
Journal of Liposome Research|February 27, 2003
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studiesJ Szebeni, L Baranyi, S Savay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton, J P Eder, A C Pavlick, et al.
Pageof 5